Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trialEur. J. Cancer 2021 Dec 22;162(xx)45-55, CA Peuker, S Yaghobramzi, C Grunert, L Keilholz, E Gjerga, S Hennig, S Schaper, IK Na, U Keller, S Brucker, T Decker, P Fasching, T Fehm, W Janni, S Kümmel, A Schneeweiss, M Schuler, D Lüftner, A Busse
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.